BOCA RATON, Fla., Oct. 09, 2023 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that management will deliver a company presentation and hold investor meetings at the Roth MKM 2023 Healthcare Opportunities Conference being held October 12, 2023 in New York City. Sensus management will also participate in the 43rd Annual Fall Clinical Dermatology Conference being held October 19-22, 2023 at the Wynn Hotel in Las Vegas.
Joe Sardano, chairman and chief executive officer of Sensus Healthcare, will deliver a 10-minute presentation at 11:15 a.m. Eastern time at the Yale Club. The presentation will not be webcast. Management will also be available for one-on-one meetings at the conference. To request a meeting with Sensus Healthcare management, please contact your Roth MKM representative or Kim Golodetz at LHA Investor Relations at kgolodetz@lhai.com.
Sensus will showcase its advancements in superficial radiotherapy at the 43rd Annual Fall Clinical Dermatology Conference, while demonstrating its SRT-100™, SRT-100+™, SRT-100 Vision™ with IG-SRT, using the latest ultrasound technology for accurate visualization of the dermis, and Sentinel™, its proprietary IT Solutions product.
Sensus Healthcare’s devices utilize the Multi-Dimensional Superficial Radiotherapy platform, which provides an alternative low-energy X-ray treatment for various types of non-melanoma skin cancer and keloids. Designed to deliver effective and safe radiotherapy, SRT offers patients a non-surgical, painless and cosmetically appealing treatment option. By enabling seamless integration with existing healthcare systems, Sensus Healthcare’s solutions ensure enhanced flexibility and convenience for healthcare providers.
Fall Clinical participants are invited to visit Sensus Healthcare at the Wynn Hotel to witness live product demonstrations and interact with the company’s knowledgeable representatives. To schedule an appointment or for more information about Sensus Healthcare’s participation, please contact Sensus Healthcare by visiting www.sensushealthcare.com.
About Sensus Healthcare
Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.
Forward-Looking Statements
This press release includes statements that are, or may be deemed, ‘forward-looking statements.’ In some cases, these statements can be identified by the use of forward-looking terminology such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential” or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words.
Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements contained in this press release, as a result of the following factors, among others: our ability to return to profitability; our ability to sell the number of SRT units we anticipate for the balance of 2023; the possibility that inflationary pressures continue to impact our sales; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation, or other aspects of our business; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; and other risks described from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
To date, we do not expect that the Russian invasion of Ukraine and global geopolitical uncertainty have not had any particular impact on our business, but we continue to monitor developments and will address them in future disclosures, if applicable.
In addition, even if future events, developments, and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release, except as may be required by applicable law. You should read carefully our “Introductory Note Regarding Forward-Looking Information” and the factors described in the “Risk Factors” section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.
Contact:
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com
# # #
